MedPath

A Multicenter, Open-label, Uncontrolled Phase II study of ONO-4538 [immune-checkpoint inhibitor] for cutaneous angiosarcoma ( Angio Check Study)

Phase 2
Conditions
Cutaneous angiosarcoma
Registration Number
JPRN-UMIN000043039
Lead Sponsor
niversity of Tsukuba
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
23
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with a current history of autoimmune disease or past history of chronic or recurrent autoimmune disease.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Response rate
Secondary Outcome Measures
NameTimeMethod
Disease control rate, overall survival, progression free survival, time to response, duration of response
© Copyright 2025. All Rights Reserved by MedPath